| Symbol | EVAX |
|---|---|
| Name | EVAXION A/S |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | DR. NEERGAARDS VEJ 5F, HOERSHOLM, DK-2970, Denmark |
| Telephone | +45 53531850 |
| Fax | — |
| — | |
| Website | https://www.evaxion-biotech.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001828253 |
| Description | Evaxion A/S want to challenge and improve todays standardized treatments with the help of our AI-Immunology platform. In the field of oncology, we create truly personalized therapies where one size fits one, and only one. Within infectious diseases, we use the technology to design next-generation vaccines to address unmet medical needs. Additional info from NASDAQ: |
Evaxion announces business update and first quarter 2026 financial results
Read moreEvaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer
Read moreNew Form 3 - Evaxion A/S <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001104659-26-048722 <b>Size:</b> 10 KB
Read moreEvaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial
Read moreNew data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma
Read moreNew Form 3/A - Evaxion A/S <b>Filed:</b> 2026-04-10 <b>AccNo:</b> 0001104659-26-042038 <b>Size:</b> 18 KB
Read more